Protecting Lives and Health
The COVID-19 pandemic is a historic global event that has been detrimental not only to people's health, but also to economies across the world. JICA believes international cooperation and solidarity are indispensable in overcoming this pandemic, and we believe it is especially vital to strengthen global health and medical systems to achieve this goal. To move forward from the pandemic and establish a resilient society that is prepared to combat infectious diseases, both now and into the future, JICA is strongly promoting JICA's Initiative for Global Health and Medicine.
*In order to contribute to the development and practical use of vaccines and pharmaceuticals that utilize Japanese
technology, we will also help develop and expand clinical trials and production systems in partner countries.
- Construction and expansion
- 341 hospitals were built,
expanded or reconstructed
(FY1973 – FY2020)
- Handwashing campaigns*
200 educational andin 48 countries
(September 2020 – March 2021)
For more information on the Handwashing for Health and Life Campaign, click here.
- Number of people with access
water due to
(FY2011 – FY2020)
- Centers for Infectious Disease
Testing and Research
- Established or expanded
core laboratories in
A case study of
JICA's cooperation in
COVID-19 in Vietnam
Starting with the construction and human resource development of the Cho Ray Hospital (1966) in southern Vietnam, JICA has since expanded its cooperation in the country to also include the Bach Mai Hospital (1998) in the north and Hue Central Hospital (2004) in central Vietnam. By establishing strong infectious disease control measures at these hospitals, these hospitals have been able to treat COVID-19 patients while continuing their regular medical services. These hospitals have also then been able to relay information on how to effectively treat COVID-19 patients to local hospitals.
Since 2003, JICA has worked with the Kitasato Daiichi Sankyo Vaccine Co., Ltd. to strengthen the manufacturing capacity of Vietnam's Center for Research and Production of Vaccines and Biologicals (POLYVAC) to produce measles and measles-rubella vaccines. Building on this experience, POLYVAC is working to now develop a domestically produced COVID-19 vaccine.
Since 2006, JICA has been partnering with the National Institute of Hygiene and Epidemiology (NIHE) to establish laboratories and support the institute's capacity development. From the early stages of the COVID-19 outbreak, NIHE has been leading the development of a nationwide rapid PCR testing system in Vietnam by utilizing the network of local laboratories it has built through its previous collaborations with JICA.